Cardiac Amyloidosis clinical trials
15 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Ultrasound Therapy In Cardiac Amyloidosis
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
- Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
- A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
- CCM OPEN HF Registry
- Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
- Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
- A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
- Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- Cardiovascular Multimodality Imaging Study
- Elevated Rate Pacing of Cardiac Amyloidosis
- CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
- PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels
- AI Echocardiographic Screening of Cardiac Amyloidosis
- 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Cardiac Amyloidosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.